CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

/C O R R E C T I O N -- Privo Technologies/

Phase 2PRV111Neutral
AI Analysis

Summary

Privo Technologies issued a correction to a news release regarding a clinical update from its Phase 2 trial of PRV111, a non-surgical therapy in development for early-stage oral cancer. The article does not contain material clinical or financial data.

Clinical Trial Data

Phase

Phase 2

Importance:1/10
Sentiment:
0.00
correctionphase 2oral cancernon-surgical therapy
Related Companies

Read the original article

Published by PR Newswire Biotech on October 7, 2026 4:31 PM

Read Original